This study is exploring treatments for non-small cell lung cancer with a mutation in the EGFR gene. The EGFR gene helps cells grow and divide. When mutated, it can cause cancer cells to grow faster. Osimertinib is a drug that blocks EGFR, potentially slowing cancer growth. Bevacizumab is another drug that stops blood vessels from forming around the tumor, cutting off its nutrients. This study aims to find out if combining these two drugs is better than using osimertinib alone.
- Participating involves taking osimertinib daily and possibly bevacizumab every 21 days. The study lasts several years with follow-ups.
- Eligibility requires a specific type of lung cancer with an EGFR mutation and no prior treatment with certain drugs.
- Risks include side effects from the drugs; however, potential benefits include longer cancer control.
Participants will undergo regular scans and tests. The study is for adults over 18 and requires a commitment to attend regular check-ups and follow protocols. If you are interested, discuss with your doctor to see if you qualify.
How understandable was the trial content above?
Hard to understand
Easy to understand